Thoughts
First Investment: 2014
EXIT - NYSE: DNA
The solutions to many of the hardest problems in agriculture, nutrition, pharmaceuticals, energy production, and chemical and material processing lie in synthetic biology. Ginkgo runs biological foundries where automation, machine learning, and analytics work in synchrony to help partners scale up the engineering and manufacture of novel enzymes, proteins, small molecules, and microbial strains.
News & Insights
Explore Companies
Syntax Bio
Programming stem cells to differentiate into desired cell types, faster
Fable Therapeutics
Using state-of-the-art machine learning models to create custom-build protein drugs
Nilo Therapeutics
Mapping the brain-body axis to achieve proper immune balance
Avicenna Biosciences
Using AI to speed through the last mile of drug discovery